Articles: prospective-studies.
-
Critical CareSESSION TYPE: Slide PresentationsPRESENTED ON: Monday, March 24, 2014 at 10:45 AM - 11:45 AMPURPOSE: Patients with severe alcohol withdrawal often require escalating doses of benzodiazepines and intubation with mechanical ventilation which leads to prolonged Intensive Care Unit(ICU) stays. Earlier studies suggest dexmedetomidine is effective in reducing benzodiazepine dosage and autonomic symptoms seen with alcohol withdrawal. We report a retrospective analysis of 53 ICU patients treated for alcohol withdrawal, conducted to compare treatment with benzodiazepine alone to those receiving dexmedetomidine as escalation or substitution therapy. ⋯ The following authors have nothing to disclose: Amit Kachalia, Kinjal Kachalia, Shivaraj Nagalli, Habibur Rahman, Ricardo Lopez, Vincent RizzoNo Product/Research Disclosure Information.
-
PleuralSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: Study objective: To evaluate the role of rigid medical thoracoscopy in the management of patients with undiagnosed exudative pleural effusion. ⋯ The following authors have nothing to disclose: Essam Hassanein, Eman Hatata, Suzan Helal, Emad Ibrahim, Ayman BaessNo Product/Research Disclosure Information.
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Indacaterol is an ultra-long-acting beta-adrenoceptor agonist which needs to be taken once a day, licensed only for the treatment of chronic obstructive pulmonary disease (COPD). It is delivered as an aerosol formulation through a dry powder inhaler. A year-long, placebo-controlled trial published in July 2010 suggests indacaterol may be significantly more effective than twice-daily formoterol in improving FEV1. There were some reductions in the need for rescue medication, but these were not significantly different; nor was there any difference in the rate of exacerbation between the 2 active treatments. We looked at our data regarding the use of Indacaterol in a tertiary care set up. This is a real life experience looking at how Indacaterol influences clinical (MRC dyspnoea scale) and physiological (Spirometry) parameters and exacerbation episodes. ⋯ The following authors have nothing to disclose: Raja Dhar, Sanjit Ray ChaudhuriNo Product/Research Disclosure Information.
-
Long-term Prognosis of Chronic Obstructive Pulmonary Disease (COPD) Patients on Home Oxygenotherapy.
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Our objective has been to assess the survival of a cohort of COPD patients in HO program and to investigate the main causes of mortality between these patients. ⋯ The following authors have nothing to disclose: María del Carmen García García, Jacinto Hernández Borge, Pedro Pires Goncalves, Carlos Antonio Aranda López, Lourdes Cañón Barroso, Estefanía Molina Ortiz, Amparo Sanz Cabrera, José Antonio Gutierrez Lara, María Teresa Gómez Vizcaíno, Ignacio Rodríguez BlancoNo Product/Research Disclosure Information.
-
Pleural Disease/Pneumothorax PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Pneumothorax continues to be a major cause of morbidity and mortality among the respiratory patients but there is paucity of data regarding aetiology, clinical profile, management and outcome of Spontaneous Pneumothorax (SP) from this part of the world. Therefore, this study was carried out to determine the aetiology, clinical presentation, management and outcomes of Spontaneous pneumothorax in a tertiary care Hospital from eastern India. ⋯ The following authors have nothing to disclose: Aparup Dhua, Sourin Bhuniya, Arunabha Datta Chaudhuri, Sumit Raytapadar, Tapan Das BairagyaNo Product/Research Disclosure Information.